Advertisement

Knight Therapeutics Inc. GUD.TO

Set alert

Price alert · GUD.TO

All alert types
11.27 CAD -0.13 -1.14%

As of Oct 30, 4:00 PM ET

11.25 Day range 11.41
5.76 52-week range 11.70
YTD
+86.28%
1 year
+94.31%
Open
11.34
Prev close
11.40
Mkt cap
1.11B
Vol
15.72K
Avg vol
82.56K
EPS
0.15
P/E
75.13
Div yield
0.00%
More statistics
Low
11.25
High
11.41
Forward P/E
43.38
Beta
-0.01
Short ratio
15.66
Inst. own
19.04%
Dividend
0.00
Ex-div date
50-d avg
10.38
200-d avg
8.50
1y target
11.65

2Y chart

Chart tools
Interval

Signals (102)
NameDateAgo
MACD: Sell SignalOct 29, 20262 days ago
RSI: OverboughtOct 19, 20261 week ago
MACD: Buy SignalSep 2, 20261 month ago
MACD: Sell SignalAug 28, 20262 months ago
SMA: BearishAug 27, 20262 months ago
MACD: Buy SignalAug 19, 20262 months ago
SMA: BullishAug 17, 20262 months ago
SMA: BearishAug 12, 20262 months ago
SMA: BullishAug 11, 20262 months ago
SMA: BearishAug 10, 20262 months ago
SMA: BullishAug 6, 20262 months ago
SMA: BearishAug 4, 20262 months ago
MACD: Sell SignalJul 10, 20263 months ago
MACD: Buy SignalJun 30, 20264 months ago
RSI: OverboughtJun 26, 20264 months ago
MACD: Sell SignalJun 23, 20264 months ago
MACD: Buy SignalJun 8, 20264 months ago
RSI: OverboughtJun 8, 20264 months ago
MACD: Sell SignalMay 21, 20265 months ago
MACD: Buy SignalMay 7, 20265 months ago
RSI: OverboughtMay 7, 20265 months ago
MACD: Sell SignalApr 16, 20266 months ago
RSI: OverboughtMar 23, 20267 months ago
MACD: Buy SignalMar 20, 20267 months ago
MACD: Sell SignalMar 3, 20268 months ago
RSI: OverboughtFeb 23, 20268 months ago
SMA: BullishFeb 13, 20268 months ago
RSI: OverboughtFeb 13, 20268 months ago
SMA: BullishFeb 12, 20268 months ago
MACD: Buy SignalFeb 2, 20269 months ago
MACD: Sell SignalJan 16, 20269 months ago
MACD: Buy SignalJan 14, 20269 months ago
SMA: BearishJan 13, 20269 months ago
SMA: BearishJan 13, 20269 months ago
MACD: Sell SignalJan 13, 20269 months ago
SMA: BullishJan 12, 20269 months ago
SMA: BullishJan 12, 20269 months ago
MACD: Buy SignalJan 12, 20269 months ago
SMA: BearishJan 8, 20269 months ago
SMA: BullishJan 7, 20269 months ago
SMA: BearishJan 2, 202610 months ago
SMA: BearishJan 2, 202610 months ago
SMA: BullishDec 31, 202510 months ago
SMA: BullishDec 29, 202510 months ago
SMA: BearishDec 19, 202510 months ago
SMA: BullishDec 10, 202510 months ago
SMA: BullishDec 10, 202510 months ago
SMA: BearishDec 8, 202510 months ago
SMA: BearishDec 8, 202510 months ago
MACD: Sell SignalNov 25, 202511 months ago
SMA: BullishNov 6, 202511 months ago
SMA: BullishNov 6, 202511 months ago
MACD: Buy SignalOct 20, 20251 year ago
RSI: OversoldOct 14, 20251 year ago
SMA: BearishOct 7, 20251 year ago
SMA: BullishOct 6, 20251 year ago
SMA: BearishOct 2, 20251 year ago
RSI: OversoldOct 2, 20251 year ago
SMA: BullishOct 1, 20251 year ago
SMA: BearishSep 30, 20251 year ago
RSI: OversoldSep 26, 20251 year ago
SMA: BearishSep 17, 20251 year ago
MACD: Sell SignalSep 2, 20251 year ago
MACD: Buy SignalAug 22, 20251 year ago
MACD: Sell SignalAug 21, 20251 year ago
MACD: Buy SignalAug 20, 20251 year ago
MACD: Sell SignalAug 15, 20251 year ago
RSI: OverboughtAug 11, 20251 year ago
RSI: OverboughtAug 7, 20251 year ago
MACD: Buy SignalAug 5, 20251 year ago
MACD: Sell SignalJul 30, 20251 year ago
MACD: Buy SignalJul 23, 20251 year ago
MACD: Sell SignalJul 21, 20251 year ago
MACD: Buy SignalJul 3, 20251 year ago
SMA: BullishJul 2, 20251 year ago
SMA: BearishJun 19, 20251 year ago
MACD: Sell SignalJun 19, 20251 year ago
SMA: BullishJun 5, 20251 year ago
MACD: Buy SignalJun 4, 20251 year ago
MACD: Sell SignalMay 9, 20251 year ago
SMA: BearishMay 8, 20251 year ago
MACD: Buy SignalApr 25, 20251 year ago
SMA: BullishApr 24, 20251 year ago
SMA: BearishApr 7, 20251 year ago
MACD: Sell SignalMar 27, 20251 year ago
RSI: OverboughtMar 19, 20251 year ago
SMA: BullishMar 11, 20251 year ago
MACD: Buy SignalMar 11, 20251 year ago
RSI: OverboughtMar 11, 20251 year ago
SMA: BearishMar 7, 20251 year ago
SMA: BullishMar 4, 20251 year ago
SMA: BearishFeb 28, 20251 year ago
MACD: Sell SignalFeb 11, 20251 year ago
MACD: Buy SignalFeb 6, 20251 year ago
MACD: Sell SignalFeb 3, 20251 year ago
RSI: OverboughtJan 28, 20251 year ago
RSI: OverboughtJan 24, 20251 year ago
SMA: BullishJan 16, 20251 year ago
MACD: Buy SignalJan 16, 20251 year ago
MACD: Sell SignalJan 15, 20251 year ago
SMA: BearishJan 13, 20251 year ago
MACD: Buy SignalDec 23, 20241 year ago

Key statistics

Market cap
1.11B
Enterprise value
1.03B
Trailing P/E
75.20
Forward P/E
43.38
PEG ratio
0.00
Price / sales
2.02
Price / book
1.39
EPS (TTM)
0.15
Beta
-0.01
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
2.72%
Revenue (TTM)
547.31M
Revenue growth
34.30%
Free cash flow
63.38M
Total cash
121.17M
Total debt
34.28M
Return on equity
1.91%
Shares outstanding
98.23M
Short % of float
0.00%
50-day average
10.38
200-day average
8.50

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 11.65 +3.4% upside
Target (low)
10.80
Target (mean)
11.65
Target (high)
14.00
Ratings (0m) 7 7 buy · 0 hold · 0 sell
  • Strong buy3
  • Buy4
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate 0.01.

Earnings history

Upgrades / downgrades

GUD.TO analyst upgrades and downgrades
DateFirmActionFromTo
Mar 6, 2024Raymond JamesmainOutperformOutperform

About Knight Therapeutics Inc.

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson's disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson's disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease. Further, it offers Niktimvo; Zynyz; Gemtesa; Orgovyx; Myfembree; Onicit; Jornay PM and Crexont capsules; and Palbocil and Bapocil for treatment of patients with hormone receptor positive. Additionally, it provides finances to other life science companies; and invests in life sciences venture capital funds. The company was incorporated in 2013 and is based in Montreal, Canada.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Canada
Website
knighttx.com

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on GUD.TO — it syncs with the Stock Master app.

Insider holders

GUD.TO insider holders
InsiderRelationLatest transactionDateShares held
Bosano (Leopoldo Agustin)Senior Officer of IssuerExercise of rightsMar 22, 202619,476
Emblem (Susan Caroline)Senior Officer of IssuerAcquisition or disposition under a purchase/ownership planSep 14, 202646,311
Gale (James)Director of IssuerExercise of optionsApr 12, 202652,997
Goodman (Jonathan Ross)Director of IssuerAcquisition or disposition under a purchase/ownership planSep 14, 20261,036,111
Khouri, AmalSenior Officer of IssuerAcquisition or disposition under a purchase/ownership planSep 14, 2026200,810
Lande (Robert Nathaniel)Director of IssuerAcquisition or disposition in the public marketMay 13, 2026223,178

Fund ownership

GUD.TO fund ownership
Holder% heldSharesValueReported
Artisan Partners Funds Inc.-Artisan International Explorer Fund1.41%1,390,45115.68MJun 29, 2026
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.0.86%841,3639.49MJul 30, 2026
DFA INVESTMENT TRUST CO-The Canadian Small Company Series0.49%484,4005.46MJul 30, 2026
DFA INVESTMENT DIMENSIONS GROUP INC-Intl Core Eqy. 2 PORT.0.38%372,4914.20MJul 30, 2026
Dimensional ETF Trust-Dimensional International Small Cap Value ETF0.31%304,6993.44MJul 30, 2026
Old Westbury Funds Inc-Old Westbury Small & Mid Cap Strategies Fund0.25%246,6142.78MJul 30, 2026
Advertisement